Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results

WALTHAM, Mass., March 15, 2016 -- Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s fourth quarter and year-end 2015 financial results.

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com. 

About Interleukin Genetics.

Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions.  The products empower individuals and their healthcare providers to manage existing health and wellness through genetics-based insights and actionable guidance.  Interleukin Genetics leverages its research, intellectual property, and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market.  The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels.  Interleukin Genetics’ lead products include its proprietary PerioPredict genetic test for periodontal disease and its Inherent Health® line of genetic tests.  Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvements Amendments (CLIA).  For more information, please visit www.ilgenetics.com.

Investor Contacts:
Hans Vitzthum
LifeSci Advisors, LLC.
(212) 915-2568
[email protected]